Therefore, by acting on TLR, TREM-1, NLRP3, FcγR and FcεR signaling pathways, ibrutinib and acalabrutinib may compromise innate immune responses of granulocytes against bacterial and fungal infections, but may also provide protection against damaging inflammatory responses of neutrophils and eosinophils as well as allergic responses of basophils and mast cells (Table 3). Here, NLRP3 is linked to fungal infectious disease.